“ Gene editing is a promising, complex technology, which will take many years to develop into a therapy for people with CF. By investing in this research now, we are laying the foundation to develop what we hope will be a transformative treatment for people with CF, especially those who can’t take CFTR modulators. ”

Steven Rowe, MD – Executive Vice President and Chief Scientific Officer at Cystic Fibrosis Foundation